In this context, the current study aimed to evaluate the anti-tumoral efficacy of a SWCNT conjugate, based on double functionalization with carboxyl groups and the anti-tumor drug cisplatin (SWCNT-COOH-CDDP), in the modulation of the PI3K/Akt/mTOR signaling pathway in MDA-MB-231 triple-negative breast cancer cells. This evidence concerns the gene AKT1 and triple-negative breast carcinoma.